🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn more about how clinical trials can offer new and potentially more effective treatments and how these trials help researchers better understand the disease! Watch now on Medlive 🔗: bit.ly/3Je97ZZ

✔️ New+emerging therapies ✔️ Guideline-driven care pathways ✔️ Real-world clinical insights In partnership w/ Medlive and National Organization for Rare Disorders (NORD), this is a must-watch #CME credit program for clinicians treating cholestatic liver diseases: 🔗liver.fyi/mlpbc2. 🧵2/2

Join LUGPA and Medlive for our Virtual Crossfire program, "Advancing #mHSPC Treatment: Recent Clinical Data with Doublet ARPI + ADT Therapy." Access on-demand: medlive.com/cancerhcp/show…

Living with IgA Nephropathy (#IgAN)? #NORD invites you to a FREE patient education activity—watch on demand to learn about new #IgANephropathy treatments, clinical guidance, and care strategies for you and your doctor: bit.ly/3T7FeQd Supported by Medlive,

Hear firsthand how Latina women fight triple negative breast cancer and find support within the breast cancer community! Watch now on Medlive 🔗: bit.ly/3Je97ZZ

New #CME Education for Clinicians Treating Respiratory Disease  Patients with type 2 (T2) inflammatory conditions, including #asthma, #COPD with overlapping features, and other eosinophilic-driven diseases.  bit.ly/43jGSCZ   Medlive

Managing ASCVD risk means looking beyond LDL-C. Learn how to assess Lp(a), lower LDL-C early, and tackle residual risk. Two #CME sessions drop 7/10 via Medlive: • Lp(a) & LDL-C in ASCVD • Strategies for residual risk bit.ly/4lBDjPJ #Cardiology #ASCVD #MedEd

Managing #ASCVD means looking beyond LDL-C. Don’t miss our new CME sessions with Medlive and National Lipid Association on Lp(a), early LDL-C lowering, and emerging therapies. 💻 Watch for #CME credit: bit.ly/4lBDjPJ • Lp(a) & LDL-C in ASCVD • Strategies for residual risk

Available on demand: LUGPA & Medlive's latest Crossfire Series presentation, "Finding the Right Fit for #Immunotherapy: Considerations for High-Risk #NMIBC." Access here: medlive.com/cancerhcp/show…

Choosing the right treatment for CLL can feel overwhelming. Learn how fixed-duration treatments may offer treatment-free periods instead of ongoing therapy Medlive. bit.ly/4iWDch1 #PatientEducation #MedEd

Earn 1.0 AMA PRA Category 1 credit from @LUGPA & Medlive’s "Readouts in #NMIBC & #ProstateCancer." Watch now: medlive.com/cancerhcp/show…

A support system during your cancer journey can make a big difference. Hear about how Claudia's support system, how they helped her, and her cancer journey. Watch now on Medlive! 👉🏾 bit.ly/3Je97ZZ

Despite available #MedicalInformation, many #patients feel uninformed when making care decisions. This #clinician-patient disconnect is rooted in a lack of shared understanding. In our latest blog post, we dive deeper into how we can bridge this gap. 🔗 bit.ly/4m76QkS

Severe itching from PBC can impact daily life. Hear one patient’s story and find out what can help. Watch now: liver.fyi/MLPBC24web Medlive

In collaboration with Medlive, we're breaking new ground in digital Alzheimer's education, and we're excited to share the latest outcomes at #AAIC25 next week in Toronto. Our research poster (#108349), co-authored by BrightFocus Foundation's Nancy Lynn Keach, and

📣 Only 3 days left! Join us at #AAIC25 as we share powerful findings from our poster presentation. Explore how patient and provider perspectives diverge in the use of anti-amyloid therapies. BrightFocus Foundation National Infusion Center Association (NICA) 🔍 Dive into the full story here: bit.ly/46XV9Z9